Share
Robert Eno
HeartBeam, Inc., a medical technology company transforming cardiac diagnostics through its proprietary 3D ECG technology, has appointed Chief Executive Officer Robert Eno to its Board of Directors, expanding the board from eight to nine members.
The move reinforces strategic alignment between executive leadership and board oversight as the company accelerates toward commercialization.
Eno joined HeartBeam as President in January 2023 and was elevated to CEO in October 2024. With over 30 years of experience in launching breakthrough technologies and scaling medtech businesses, Eno’s leadership has been pivotal in positioning HeartBeam at the forefront of personalized cardiac diagnostics.
Under Eno’s direction, the company achieved a key milestone in December 2024, receiving FDA clearance for its patented 3D ECG platform - an innovation that captures cardiac signals in three non-coplanar vectors and synthesizes them into a 12-lead ECG, enabling physicians to diagnose cardiac events with greater precision. HeartBeam submitted its 12-lead ECG synthesis software to the FDA in January 2025, with commercial launch anticipated pending regulatory clearance.
As HeartBeam prepares for market entry, it has launched an Early Access Program designed to refine clinical workflows, validate real-world usability, and build early momentum through key opinion leader engagement.
Eno’s addition to the board brings hands-on executive insight to strategic decision-making and ensures close alignment as the company enters its commercialization phase.
Prior to HeartBeam, Eno served as CEO of Preview Medical, advancing AI-powered diagnostics for solid tumors. He also held leadership roles at HeartFlow, OptiMedica, NeoGuide Systems, and Avantec Vascular, where he drove product development and go-to-market strategies in cardiology and diagnostic imaging.
Eno holds an MBA from Stanford Graduate School of Business and a BA with Honors and Distinction from Stanford University.
His appointment to the Board marks another step forward in HeartBeam’s mission to deliver advanced, accessible cardiac diagnostics that empower clinicians and improve patient outcomes worldwide.
Related posts
.jpg "Integra LifeSciences Appoints Dr. Raymond Turner as Chief Medical Officer")
